ProSci

PD1 Recombinant Protein

Product Code:
 
PSI-RF16000-01
Product Group:
 
Recombinant Proteins
Supplier:
 
ProSci
Regulatory Status:
 
RUO
Target Species:
 
Human
Application:
 
Western Blot (WB)
Storage:
 
Lyophilized Protein should be stored at -20˚C or lower for long term storage. Upon reconstitution, working aliquots should be stored at -20˚C or -70˚C. Avoid repeated freeze-thaw cycles.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
PSI-RF16000-01-0.1mg0.1mg£686.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • Show All

Further Information

Additional Names:
PDCD1, PD1, CD279, SLEB2, hPD-1, hPD-l, PD-1
Application Note:
This recombinant protein can be used for WB. For research use only.
Background:
Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.
Background References:
  • Ishida Y., et al., 1992, EMBO J. 11 (11): 3887?95.
  • Blank C., et al., 2007, Cancer Immunol. Immunother. 56 (5): 739?45.
  • Agata Y., et al., 1996, Int. Immunol. 8 (5): 765?72.
  • Freeman GJ., et al., 2000, J. Exp. Med. 192 (7): 1027?34.
Biological Activity:
(1) Measured by its binding ability in a functional ELISA. Immobilized Human PD-1, His Tag at 2 ug/mL (100 uL/well) can bind Human PD-L1, Fc Tag with a linear range of 0.8-250 ng/mL. (2) Measured by its binding ability in a functional ELISA. Immobilized Human PD-1, His Tag at 0.2 ug/mL (100 ul/well) can bind Human PD-L2, Fc Tag with a linear range of 0.16-2.5 ug/mL.
Buffer:
PBS, pH7.4
Fusion Tag:
His Tag
NCBI Gene ID #:
5133
NCBI Official Name:
programmed cell death 1
NCBI Official Symbol:
PDCD1
NCBI Organism:
Homo sapiens
Physical State:
Lyophilized
Predicted Molecular Weight:
16.77 kDa
Protein Accession #:
NP_005009.2
Purity:
>95% as determined by SDS-PAGE.
Recombinant Protein Sequence:
Thr32-Gly402
Source:
HEK293 cells
Swissprot #:
Q15116

Documents